While individuals with severe allergies reported more reactions after receiving a COVID-19 mRNA vaccine than those without allergies, nearly all were able to safely complete the series, according to an Oct. 27 study in JAMA Network Open. Researchers at Boston-based Mass General Brigham and Harvard Medical School used electronic health records of 52,998 employees, of whom 97.6 percent received both doses of vaccine, and 0.9 percent reported a history of high-risk allergy.
